文献速递糖尿病肥胖与代谢综合征

新型脂肪因子WISP1与胰岛素抵抗相关并损害人肌管和小鼠肝细胞的胰岛素作用

The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes.
PubMed 文献 · Diabetologia · 2018-05-12

研究比较正常体重男性与肥胖伴或不伴2型糖尿病男性的血清及内脏脂肪WISP1水平,并在人骨骼肌细胞和小鼠肝细胞中观察WISP1对胰岛素信号的影响。肥胖男性循环WISP1水平和内脏脂肪WISP1表达升高且与血糖正相关、与脂联素负相关;WISP1在体外损害胰岛素信号、糖原合成和糖异生基因抑制。

要点

  • 肥胖男性循环WISP1水平及内脏脂肪WISP1表达高于正常体重男性,且不依赖糖尿病状态。
  • 循环WISP1与OGTT血糖正相关、与脂联素负相关。
  • WISP1在体外损害人肌管和小鼠肝细胞的胰岛素信号及代谢作用。

核心结论

  • 肥胖者循环WISP1水平及内脏脂肪WISP1表达升高,不依赖血糖状态;WISP1损害肌肉和肝脏细胞的胰岛素信号。

研究设计与样本

  • 收集正常体重男性(对照组,n=33)及接受手术的肥胖伴2型糖尿病(n=46)和不伴2型糖尿病(n=56)男性的血清和内脏脂肪活检,用ELISA测循环WISP1、实时定量RT-PCR测WISP1 mRNA表达;原代人骨骼肌细胞和小鼠AML12肝细胞与WISP1及胰岛素共孵育后用蛋白质印迹分析胰岛素信号,并检测糖原合成和糖异生。

主要发现

  • 肥胖男性循环WISP1水平高于正常体重男性(均值[95%CI]:70.8[55.2,86.4]ng/l vs 42.6[28.5,56.6]ng/l,p<0.05),且不依赖糖尿病状态。
  • 肥胖男性内脏脂肪WISP1表达较正常体重男性高1.9倍(p<0.05)。
  • 循环WISP1水平与OGTT血糖及循环血红素加氧酶-1正相关,与脂联素水平负相关。
  • 在原代人骨骼肌细胞和AML12肝细胞中,重组WISP1抑制胰岛素受体、Akt及其底物糖原合成酶激酶3β、FOXO1和p70S6激酶的磷酸化,并抑制胰岛素刺激的糖原合成及糖异生基因抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Wingless-type (Wnt) inducible signalling pathway protein-1 (WISP1) has been recently identified as a proinflammatory adipokine. We examined whether WISP1 expression and circulating levels are altered in type 2 diabetes and whether WISP1 affects insulin signalling in muscle cells and hepatocytes. METHODS: Serum and visceral adipose tissue (VAT) biopsies, for analysis of circulating WISP1 levels by ELISA and WISP1 mRNA expression by real-time quantitative RT-PCR, were collected from normal-weight men (control group, n = 33) and obese men with (n = 46) and without type 2 diabetes (n = 56) undergoing surgery. Following incubation of primary human skeletal muscle cells (hSkMCs) and murine AML12 hepatocytes with WISP1 and insulin, insulin signalling was analysed by western blotting. The effect of WISP1 on insulin-stimulated glycogen synthesis and gluconeogenesis was investigated in hSkMCs and murine hepatocytes, respectively. RESULTS: Circulating WISP1 levels were higher in obese men (independent of diabetes status) than in normal-weight men (mean [95% CI]: 70.8 [55.2, 86.4] ng/l vs 42.6 [28.5, 56.6] ng/l, respectively; p < 0.05). VAT WISP1 expression was 1.9-fold higher in obese men vs normal-weight men (p < 0.05). Circulating WISP1 levels were positively associated with blood glucose in the OGTT and circulating haem oxygenase-1 and negatively associated with adiponectin levels. In hSkMCs and AML12 hepatocytes, recombinant WISP1 impaired insulin action by inhibiting phosphorylation of insulin receptor, Akt and its substrates glycogen synthase kinase 3β, FOXO1 and p70S6 kinase, and inhibiting insulin-stimulated glycogen synthesis and suppression of gluconeogenic genes. CONCLUSIONS/INTERPRETATION: Circulating WISP1 levels and WISP1 expression in VAT are increased in obesity independent of glycaemic status. Furthermore, WISP1 impaired insulin signalling in muscle and liver cells.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hörbelt T, Tacke C, Markova M, et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia. 2018. PMID: 29754289. doi:10.1007/s00125-018-4636-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。